#Canada #Aurora Cannabis #Edmonton #fiscal results #medical cannabis

Aurora Cannabis Reports Strong Fiscal Q3 2026 Results

Date: February 4, 2026

Aurora Cannabis Inc., a prominent player in the global medical cannabis market, has released its financial and operational results for the third quarter of fiscal 2026, ending on December 31, 2025.

The company has reported a 7% increase in total net revenue year-over-year, totaling $94.2 million. Impressively, the global medical cannabis segment experienced a 12% rise, contributing $76.2 million to the total, marking a record for the company. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at $18.5 million, while adjusted net income reached $7.2 million. Furthermore, Aurora generated free cash flow of $15.5 million during the quarter.

Highlights of Q3 2026

During the quarter, Aurora achieved significant milestones:

• - Increased Medical Revenue: The medical cannabis segment has shown robust growth, primarily driven by expansion in key international markets such as Germany and Poland. This segment accounted for 81% of Aurora's consolidated net revenue.
• - Plant Propagation Growth: Additionally, plant propagation revenue surged to $11.3 million, reflecting a 27% increase from the previous year.
• - Strong Financial Position: Aurora maintained a solid balance sheet with $154.4 million in cash and investments, enhancing its capacity for future growth initiatives without debt restrictions.

Focus on Medical Cannabis

Miguel Martin, Executive Chairman and CEO of Aurora, stated, "We have established a commanding leadership position within the high-margin global medical cannabis market." He emphasized that the company's unwavering dedication to expanding its medical cannabis sector through strategic investments and operational efficiencies garnered significant results.

However, the consumer cannabis segment witnessed a 48% decline, generating only $5.2 million in revenue. Aurora intends to reallocate resources and products primarily towards its medical cannabis focus, reflecting an industry trend prioritizing higher-margin businesses over consumer segments.

Strategic Decisions and Future Outlook

Aurora's strategic adjustments underscore its commitment to maintaining strong margins and driving future growth. Effective in the fourth quarter of FY26, the company will exit certain lower-margin consumer markets in Canada, optimizing resources towards the lucrative medical cannabis sector.

In addition to business restructuring, Aurora has engaged in the Bevo Transaction, exchanging common shares for preferred shares with Bevo Agtech, thus aligning its interests in plant propagation with its wider business strategy. Upon completion, this transition is expected to yield capital for further investments in cultivation and potential mergers and acquisitions.

Looking ahead, Aurora anticipates an annual global medical cannabis revenue increase between $269 million and $281 million for the fiscal year 2026. The company expects healthy margin growth and solid EBITDA, emphasizing continuous commitment to profitable expansion.

Conclusion

As Aurora Cannabis continues to navigate the evolving cannabis landscape, its latest quarterly results reflect strategic focus and an agile approach to market demands. With a commitment to excellence and patient care, Aurora aims to solidify its global leadership in the medical cannabis space while tactically optimizing its portfolio for maximum efficiency and profitability.

For more information, visit Aurora Cannabis.